NPPB and type 2 diabetes mellitus: Based on extensive and solid clinical evidence, a recent Consensus Statement of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) [11] detailed the importance of assessing the levels of cardiac biomarker N-terminal-pro B-type Natriuretic Peptide (NT-proBNP) to evaluate T2DM patients at risk of HF in pre-failure or “heart stress” (HS), a new term introduced to identify asymptomatic individuals with risk factors and elevated plasma NPs, irrespective of the presence or absence of structural heart disease or cardiac dysfunction.